Tammo Ostendorf

List of Publications by Year
in descending order

54 papers	3,245 citations	159585 30 h-index	175258 52 g-index
54 all docs	54 docs citations	54 times ranked	3715 citing authors

#	Article	IF	Citations
1	Key metalloproteinase-mediated pathways in the kidney. Nature Reviews Nephrology, 2021, 17, 513-527.	9.6	46
2	New Aspects of Kidney Fibrosisâ€“From Mechanisms of Injury to Modulation of Disease. Frontiers in Medicine, 2021, 8, 814497.	2.6	21
3	The YB-1:Notch-3 axis modulates immune cell responses and organ damage in systemic lupus erythematosus. Kidney International, 2020, 97, 289-303.	5.2	18
4	The nucleic acid binding protein YB-1â€“controlled expression of CXCL-1 modulates kidney damage inÂliver fibrosis. Kidney International, 2020, 97, 741-752.	5.2	13
5	High-fat diet-induced obesity causes an inflammatory microenvironment in the kidneys of aging Long-Evans rats. Journal of Inflammation, 2019, 16, 14.	3.4	21
6	A Novel Role for GATA3 in Mesangial Cells in Glomerular Development and Injury. Journal of the American Society of Nephrology: JASN, 2019, 30, 1641-1658.	6.1	31
7	Identification of platelet-derived growth factor C as a mediator of both renal fibrosis and hypertension. Kidney International, 2019, 95, 1103-1119.	5.2	14
8	CD44 is required for the pathogenesis of experimental crescentic glomerulonephritis and collapsing focal segmental glomerulosclerosis. Kidney International, 2018, 93, 626-642.	5.2	52
9	Complement C5a receptors C5L2 and C5aR in renal fibrosis. American Journal of Physiology - Renal Physiology, 2018, 314, F35-F46.	2.7	24
10	YB-1 increases glomerular, but decreases interstitial fibrosis in CNI-induced nephropathy. Clinical Immunology, 2018, 194, 67-74.	3.2	10
11	<scp>YB</scp>â€1 orchestrates onset and resolution of renal inflammation via <scp>IL</scp>10 gene regulation. Journal of Cellular and Molecular Medicine, 2017, 21, 3494-3505.	3.6	23
12	Cold Shock Proteins Mediate GN with Mesangioproliferation. Journal of the American Society of Nephrology: JASN, 2016, 27, 3678-3689.	6.1	10
13	Therapeutic nuclear shuttling of YB-1 reduces renal damage and fibrosis. Kidney International, 2016, 90, 1226-1237.	5.2	32
14	IL-6 Trans-Signaling Drives Murine Crescentic GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 132-142.	6.1	45
15	Macrophage Migration Inhibitory Factor Mediates Proliferative GN via CD74. Journal of the American Society of Nephrology: JASN, 2016, 27, 1650-1664.	6.1	59
16	Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery. Scientific Reports, 2015, 5, 14685.	3.3	8
17	Diffusionâ€weighted MRI does not reflect kidney fibrosis in a rat model of fibrosis. Journal of Magnetic Resonance Imaging, 2015, 42, 990-998.	3.4	44
18	Role of Platelet-Derived Growth Factor-CC in Capillary Rarefaction in Renal Fibrosis. American Journal of Pathology, 2015, 185, 2132-2142.	3.8	19

#	Article	IF	Citations
19	Common histological patterns in glomerular epithelial cells in secondary focal segmental glomerulosclerosis. Kidney International, 2015, 88, 990-998.	5.2	57
20	Platelet-derived growth factors (PDGFs) in glomerular and tubulointerstitial fibrosis. Kidney International Supplements, 2014, 4, 65-69.	14.2	44
21	Gp130-dependent signaling in the podocyte. American Journal of Physiology - Renal Physiology, 2014, 307, F346-F355.	2.7	20
22	Calcineurin-mediated YB-1 Dephosphorylation Regulates CCL5 Expression during Monocyte Differentiation. Journal of Biological Chemistry, 2014, 289, 21401-21412.	3.4	33
23	Detection of Activated Parietal Epithelial Cells on the Glomerular Tuft Distinguishes Early Focal Segmental Glomerulosclerosis from Minimal Change Disease. American Journal of Pathology, 2014, 184, 3239-3248.	3.8	81
24	PDGF and the progression of renal disease. Nephrology Dialysis Transplantation, 2014, 29, i45-i54.	0.7	82
25	Late angiotensin <scp>II</scp> receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms. Journal of Pathology, 2013, 229, 672-684.	4.5	12
26	Biological responses to PDGF-AA versus PDGF-CC in renal fibroblasts. Nephrology Dialysis Transplantation, 2013, 28, 889-900.	0.7	16
27	Growth arrestâ€“specific protein 1 is a novel endogenous inhibitor of glomerular cell activation and proliferation. Kidney International, 2013, 83, 251-263.	5.2	24
28	A Novel, Dual Role of CCN3 in Experimental Glomerulonephritis. American Journal of Pathology, 2012, 180, 1979-1990.	3.8	25
29	The PDGF family in renal fibrosis. Pediatric Nephrology, 2012, 27, 1041-1050.	1.7	67
30	Extracellular YB-1 Blockade in Experimental Nephritis Upregulates Notch-3 Receptor Expression and Signaling. Nephron Experimental Nephrology, 2011, 118, e100-e108.	2.2	41
31	Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis. Nephrology Dialysis Transplantation, 2011, 26, 3131-3143.	0.7	24
32	Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nature Reviews Nephrology, 2010, 6, 643-656.	9.6	517
33	PDGF-C Mediates Glomerular Capillary Repair. American Journal of Pathology, 2010, 177, 58-69.	3.8	38
34	Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. Nephrology Dialysis Transplantation, 2009, 24, 2755-2762.	0.7	26
35	Cytokines and Growth Factors. , 2009, , 243-265.		0
36	PDGF-C Is a Proinflammatory Cytokine that Mediates Renal Interstitial Fibrosis. Journal of the American Society of Nephrology: JASN, 2008, 19, 281-289.	6.1	103

#	Article	IF	Citations
37	Complement C5 Mediates Experimental Tubulointerstitial Fibrosis. Journal of the American Society of Nephrology: JASN, 2007, 18, 1508-1515.	6.1	100
38	PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrology Dialysis Transplantation, 2007, 22, 1323-1331.	0.7	55
39	Renal side effects of anti-VEGF therapy in man: a new test system. Nephrology Dialysis Transplantation, 2007, 22, 2778-2780.	0.7	19
40	Treatment targets in renal fibrosis. Nephrology Dialysis Transplantation, 2007, 22, 3391-3407.	0.7	132
41	Mesenchymal Stem Cells Prevent Progressive Experimental Renal Failure but Maldifferentiate into Glomerular Adipocytes. Journal of the American Society of Nephrology: JASN, 2007, 18, 1754-1764.	6.1	265
42	The Role of PDGF-D in Mesangioproliferative Glomerulonephritis. , 2007, 157, 153-158.		12
43	Pro-fibrogenic potential of PDGF-D in liver fibrosis. Journal of Hepatology, 2007, 46, 1064-1074.	3.7	164
44	Antagonism of PDGF-D by Human Antibody CR002 Prevents Renal Scarring in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2006, 17, 1054-1062.	6.1	64
45	Y-Box Protein 1 Mediates PDGF-B Effects in Mesangioproliferative Glomerular Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 2985-2996.	6.1	42
46	Inducible Nitric Oxide Synthaseâ€“Derived Nitric Oxide Promotes Glomerular Angiogenesis via Upregulation of Vascular Endothelial Growth Factor Receptors. Journal of the American Society of Nephrology: JASN, 2004, 15, 2307-2319.	6.1	25
47	PDGF-C Expression in the Developing and Normal Adult Human Kidney and in Glomerular Diseases. Journal of the American Society of Nephrology: JASN, 2003, 14, 1145-1153.	6.1	69
48	A Fully Human Monoclonal Antibody (CR002) Identifies PDGF-D as a Novel Mediator of Mesangioproliferative Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2003, 14, 2237-2247.	6.1	87
49	PDGF-D and Renal Disease: Yet Another One of Those Growth Factors?. Journal of the American Society of Nephrology: JASN, 2003, 14, 2690-2691.	6.1	12
50	The Effects of Platelet-Derived Growth Factor Antagonism in Experimental Glomerulonephritis Are Independent of the Transforming Growth Factorâ€“î² System. Journal of the American Society of Nephrology: JASN, 2002, 13, 658-667.	6.1	46
51	Expression of a Novel PDGF Isoform, PDGF-C, in Normal and Diseased Rat Kidney. Journal of the American Society of Nephrology: JASN, 2002, 13, 910-917.	6.1	62
52	Selective Cyclooxygenase-2 Inhibition Impairs Glomerular Capillary Healing in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2002, 13, 1261-1270.	6.1	40
53	Specific Antagonism of PDGF Prevents Renal Scarring in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2001, 12, 909-918.	6.1	112
54	Novel Approach to Specific Growth Factor Inhibition in Vivo. American Journal of Pathology, 1999, 154, 169-179.	3.8	239